Big Pharma’s business-as-usual playbook relies on egregious pricing practices and rhetoric designed to set and keep drug prices high.

Drug prices in the United States are out of control as a direct result of the egregious pricing and anti-competitive practices of brand name pharmaceutical companies. Rising prescription drug prices threaten the affordability of our health care system, the long-term health of our nation and the vitality of our entire economy. Public opinion research finds as many as one-in-three Americans experience financial difficulty, either as a patient themselves or through a family member, affording prescription drugs. CSRxP has developed market-based solutions to restore a functioning market and lower prices for patients by increasing list price transparency, promoting competition and actual innovation and focusing on better value for patients, not better value for pharmaceutical companies.

Apr 3, 2025

CSRxP STATEMENT ON SENATE JUDICIARY PASSAGE OF BIPARTISAN, MARKET-BASED SOLUTIONS TO HOLD BIG PHARMA ACCOUNTABLE, LOWER DRUG PRICES

Committee Markup Advances Legislation to Crack Down on Big Pharma’s Anti-Competitive

Apr 2, 2025

BIG PHARMA WATCH: PFIZER AVOIDED PAYING BILLIONS IN U.S. TAXES THROUGH “EGREGIOUS TAX GIMMICK”

Big Pharma Giant Used “Round-Tripping” Tax Avoidance Scheme to Attribute U.S. Sales

Apr 2, 2025

FACT SHEET: BIG PHARMA’S PATENT ABUSE COSTS AMERICAN PATIENTS, TAXPAYERS AND THE U.S. HEALTH CARE SYSTEM BILLIONS OF DOLLARS

Big Pharma’s Anti-Competitive Tactics Are The Root Cause of Out-of-Control

Mar 18, 2025

CSRXP ANALYSIS FINDS BIG PHARMA’S DIRECT-TO-CONSUMER (DTC) ADVERTISING COSTS U.S. TAXPAYERS BILLIONS OF DOLLARS

Study Finds Reducing or Taxing Brand Name Drug Companies’ Nearly $14 Billion in Annual

Apr 3, 2025

CSRxP STATEMENT ON SENATE JUDICIARY PASSAGE OF BIPARTISAN, MARKET-BASED SOLUTIONS TO HOLD BIG PHARMA ACCOUNTABLE, LOWER DRUG PRICES

Committee Markup Advances Legislation to Crack Down on Big Pharma’s Anti-Competitive

Apr 2, 2025

BIG PHARMA WATCH: PFIZER AVOIDED PAYING BILLIONS IN U.S. TAXES THROUGH “EGREGIOUS TAX GIMMICK”

Big Pharma Giant Used “Round-Tripping” Tax Avoidance Scheme to Attribute U.S. Sales

Apr 2, 2025

FACT SHEET: BIG PHARMA’S PATENT ABUSE COSTS AMERICAN PATIENTS, TAXPAYERS AND THE U.S. HEALTH CARE SYSTEM BILLIONS OF DOLLARS

Big Pharma’s Anti-Competitive Tactics Are The Root Cause of Out-of-Control

Mar 18, 2025

CSRXP ANALYSIS FINDS BIG PHARMA’S DIRECT-TO-CONSUMER (DTC) ADVERTISING COSTS U.S. TAXPAYERS BILLIONS OF DOLLARS

Study Finds Reducing or Taxing Brand Name Drug Companies’ Nearly $14 Billion in Annual

Videos

Watch and learn about Big Pharma’s price-gouging techniques that are the cause of out-of-control drug prices.

Fact Sheets

Get the facts on Big Pharma’s anti-competitive tactics, like price-gouging and patent abuse that keeps drug prices high.

Infographics

Learn about how Big Pharma is driving the Rx drug pricing crisis with our infographics.

Polling

See recent surveys on American voters’ opinions on Big Pharma’s blame game and out-of-control drug pricing.

Join us in telling lawmakers: It’s time to hold Big Pharma accountable and lower Rx drug prices.

By signing your name, you are opting-in to receive calls and SMS/MMS messages, including autodialed and automated calls and texts, to that number from CSRxP. Msg & data rates may apply.
This field is for validation purposes and should be left unchanged.